Sparsentan: First real-world efficacy data in IgAN patients receiving SGLT2i
In this medfyle
Sparsentan is a dual-acting antagonist for angiotensin II receptor type 1 and endothelin receptor type A. SGLT2i use was prohibited during the double-blind period of the pivotal trial, but this class has since come to the fore in IgAN. This real-world study aims to build the evidence base for additive effects of combining therapy.
About this Medfyle
©2024 Infomedica-Medfyle. All rights reserved.
Source: First Real-World Evidence of Sparsentan Efficacy in Patients with IgA Nephropathy Treated with SGLT2 Inhibitors. Schanz M, et al. Presented at Kidney Week 2024; #FR-PO852.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
